Hyaluronic Acid May Be a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy

2022 ◽  
Vol 2 (1) ◽  
pp. 15-24
Author(s):  
TAKASHI MIYATA ◽  
YASUTO TOMITA ◽  
YUTA SAN-NOMIYA ◽  
TAIGO NAGAYAMA ◽  
RYOSUKE KIN ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hyaluronic Acid ◽  
Liver Dysfunction ◽  
Liver Enzymes ◽  
Laboratory Data ◽  
Radical Resection ◽  
Predictive Biomarker ◽  
Sinusoidal Obstruction Syndrome ◽  
Splenic Volume ◽  
Colorectal Cancer Patients

Background/Aim: Following oxaliplatin-based chemotherapy, approximately half of all colorectal cancer patients develop sinusoidal obstruction syndrome (SOS). SOS can be monitored by measuring splenic volume; however, obtaining this measurement is not a simple process. In this study, we evaluated changes in hyaluronic acid (HA) concentrations as a simpler marker of SOS. Patients and Methods: We measured splenic volume and laboratory data, including hyaluronic acid concentration, liver enzymes, and platelet counts, in 34 patients with colorectal cancer who underwent radical resection and who received capecitabine plus oxaliplatin (CapeOx) chemotherapy. Results: A strong correlation was identified between ≥30% increase in splenic volume and significantly elevated HA concentrations. Affected patients also had persistent thrombocytopenia and liver dysfunction compared to patients without elevated HA concentration. Conclusion: HA concentration may predict SOS in patients who receive CapeOx adjuvant chemotherapy.

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab

2013 ◽  
Vol 30 (2) ◽  
Author(s):  
Irene Guijarro-Muñoz ◽  
Antonio Sánchez ◽  
Esther Martínez-Martínez ◽  
Jose M. García ◽  
Clara Salas ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Gene Expression Profiling ◽  
Cancer Patients ◽  
Expression Profiling ◽  
Predictive Biomarker ◽  
Colorectal Cancer Patients

Modified Glasgow prognostic score as a selection marker for colorectal cancer patients with multiple metastases who can underwent primary site resection followed by multidisciplinary therapy.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 655-655
Author(s):  
Tadanobu Shimura ◽  
Yuji Toiyama ◽  
Susumu Saigusa ◽  
Hiroki Imaoka ◽  
Masato Okigami ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Laboratory Data ◽  
Multivariate Logistic Regression Analysis ◽  
Multimodality Therapy ◽  
Multivariate Logistic Regression ◽  
Multidisciplinary Therapy ◽  
Clinicopathological Findings ◽  
Multiple Metastases ◽  
Colorectal Cancer Patients

655 Background: We often encounter the colorectal cancer (CRC) patients with multiple distant metastases who rapidly progress after resection of primary tumor site due to preventing bowel obstruction, tumor bleeding and perforation. However, there has been few knowledge for identification of these patients at the present time. In this study, we evaluated the association between clinicopathological findings, including with preoperative laboratory data and survival outcome, and possibility of multimodality therapy in CRC patients with multiple metastases after resection of primary tumor lesion. Methods: Clinicopathological findings and preoperative laboratory data, including carcinoembryonic antigen (CEA) and systemic inflammatory response markers, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and modified Glasgow Prognosis Score (mGPS) for 92 CRC patients with multiple metastases from 2005 to 2014 were collected. We performed multivariate analysis for overall survival (OS) in cox proportional hazard model. In addition, we performed multivariate logistic regression analysis to evaluate the factors influencing possibility of postoperative multimodality therapy. Results: Postoperative multimodality therapy improved overall survival significantly. Among serum markers, elevated CEA, NLR, and mGPS were significant indicators of poorer OS. Multivariate analysis for OS revealed that elevated CEA (P = 0.026), mGPS (P = 0.038), and undifferentiated histology type (P = 0.02) were independent poorer prognostic factors. In addition, multivariate logistic regression analysis showed that elevated mGPS (P = 0.029) and higher age (P = 0.013) were independent risk factors for difficulty of introducing postoperative multidisciplinary therapy. Conclusions: Preoperative mGPS is useful objective marker for selection of colorectal cancer patients with multiple metastases who can undergo primary resection followed by multidisciplinary therapy.

MSI‐L/EMAST is a predictive biomarker for metastasis in colorectal cancer patients

2018 ◽  
Vol 234 (8) ◽  
pp. 13128-13136 ◽  
Author(s):  
Amir Torshizi Esfahani ◽  
Seyed Yoosef Seyedna ◽  
Ehsan Nazemalhosseini Mojarad ◽  
Ahmad Majd ◽  
Hamid Asadzadeh Aghdaei
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Predictive Biomarker ◽  
Colorectal Cancer Patients

scholarly journals RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients

2021 ◽  
Vol 146 ◽  
pp. 74-83
Author(s):  
Umberto Malapelle ◽  
Francesco Passiglia ◽  
Chiara Cremolini ◽  
Maria Lucia Reale ◽  
Francesco Pepe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Predictive Biomarker ◽  
Colorectal Cancer Patients

scholarly journals Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110070
Author(s):  
Tao Li ◽  
Guoliang Liu ◽  
Jiannan Li ◽  
Jian Cui ◽  
Xinyu Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Case Reports ◽  
Intraepithelial Neoplasia ◽  
Radical Resection ◽  
Stromal Tumor ◽  
Cancer Early Detection ◽  
Long Term Follow Up ◽  
Gastric Stromal Tumor ◽  
Colorectal Cancer Patients

Radical resection with or without adjuvant chemotherapy is a common option for stage II and III colorectal cancer. Few reports exist regarding gastric tumorigenesis, including gastric cancer, gastric intraepithelial neoplasia, and gastric stromal tumor, in patients who received this protocol as the standard treatment for colorectal cancer. We present two cases of gastric tumorigenesis in patients with colorectal cancer following radical resection combined with adjuvant chemotherapy. Both patients underwent gastrectomy and D2 lymphadenectomy for their gastric tumors; neither patient developed recurrence up to 2 years after treatment. These cases indicate that patients should be monitored closely for gastric tumorigenesis after treatment for colorectal cancer. Early detection and active surgical treatment can provide satisfactory results for colorectal cancer followed by gastric tumorigenesis. Long-term follow-up and regular examinations, especially gastroscopy, are necessary to detect gastric tumorigenesis after colorectal cancer. The focus on monitoring colorectal cancer alone in colorectal cancer patients should be changed to include a broader range of cancers in addition to precancers and other tumors, such as gastric stromal tumor.

scholarly journals Treatment results of colorectal cancer: 10-years series of UMC Ljubljana (1991-2000)

2006 ◽  
Vol 53 (2) ◽  
pp. 103-107
Author(s):  
Z. Stor ◽  
R. Juvan ◽  
F. Jelenc ◽  
S. Repse
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Colon Cancer ◽  
Survival Rate ◽  
Postoperative Mortality ◽  
Radical Resection ◽  
Stage Iii ◽  
Rank Test ◽  
R0 Resection ◽  
Colorectal Cancer Patients

In Slovenia the incidence of colorectal cancer is growing rapidly. In 1998 1022 new cases were registered. Our study compares results of two groups of patients with colorectal cancer. Patients and methods. In the period from 1.1.1991 to 31.12.2000 1478 patients with a colorectal carcinoma underwent potentially curative resection. We divided them in two groups, one operated in the first 5-years and second in later 5-years period. 5- years survival was estimated with Kaplan-Meier statistical analysis. Patients who died within 30 days after the operation were censored. Differences in survival curves between both groups were assessed by the log rank test. Results. We resected 1478 /1599 (92,4%) patients. There was 913 (61,7%) patients resected with colon cancer and 528 (35,8%) with rectal cancer and 37 (2,5%) with sinhronius tumors. R0 resection was performed in 1174 (79,4%) patients, R1 in 29 (2,0%), and R2 in 273 (18,5%) patients. Postoperative mortality rate in resected patients was 5,48% (81/1478), in the group with paliative operations was 17,35% (21/121). Overall five-years survival rate was 54,9% (56,18% for colon cancer and 52,4% for rectal cancer Five years survival rate for the patients with radical resection (R0) was 66,54% for colon cancer and 59,47% for rectal cancer. Conclusion. 5-years survival for R0-resected patients with colon cancer was in the last period from 1996 to 2000 statistically significantly better compared with the period from 1991 to 1995 (76% vs 60%) in stage I (p=0,04048) and in stage III (p=0,01842). 5-years survival for R0-resected patients with rectal cancer was significantly better in the same period (63% vs 55%) (p= 0,03627) in stage III (p=0,01663).

Sign in / Sign up

Export Citation Format

Share Document